µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ;t&q|}x"
}\"EI<$s
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ \zO.#H
6R6Ub
0
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ <>] DcA
RaJTya^
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© N"S`9B1eD(
%6m/ve
1. CD4 ,-c,3/
tyA
\QvGkcDc{
2. T cell receptor(TCR) )pWgt5:7~
VdHT3r
3. immunoglobulin superfamily (IgSF) U%q)T61
P3zUaN\c
4. selectin ewMVUq*:
1b5Z^a<u
5. anti-idiotypic antibody (¦ÁId) Xoe|]@U`
;wv[';J
6. major histocompatibility complex(MHC) t
7Q$
:@L7RZ`_
7. immunotolerance x5lVb$!G
t>bzo6cj
8. biological reponse modifier(BRM) )&c2+Y@
a"#t'\
9. immune reponse gene (Ir gene) Xb_
V\b0
`Skvqo(5:
10. reshaped antibody (or reconstituted antibody) y,D9O/VP
q\fbrv%I4
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© d^v#x[1msZ
Ia2WBs=
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ uo:RNokjJ
&CG
94
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? zEQ]5>mG
M\1CDU+*Ns
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ e,(Vy
xQ9t1b|{e
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? uKx:7"KD
Es=G' au
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) RXXHg
%`Ce#b()'
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ !'$*Z(
gwaSgV$z
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? IOHWb&N6
VwR\"8r3
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? XT^=v6^H
B>u`%Ry&
¡¡ `
nX,x-UM
ra~=i|s
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ~<1s
[Hu
-Mo4`bN
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? CI*JedO]
A
rE~6X
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? *zRig|k !H
?>7\L'n=5I
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ bK "I
9T #
SU%O \4Ty
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ jdG'sITv
\Fjasz5E'
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Bo:epus}\
J>X@g;
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1F.._5_"]
%@QxU-k_
1. CD8 iv
`G}.Bo
a;$V;3C{b&
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Xau%v5r
&pK0>2
3. immunoglobulin fold(Ig fold) x|Uwk=;X|s
t|>P9lX@
4. cadherin (Ca-dependent cell adhesion moleculers) $.C\H,H
=U84*HAv
5. idiotype-anti-idiotypic antibody immune network theory `U0XvWPr[
9ad`q+kY
6. HLA class II antigen xS,F
DPA
<=CABW
O.
7. complementarity-determining region (CDR) ~xzr8 P
#
2|biTJ
8. perforin(or pore-forming protein ,PFP) 5[g&0
6b*xhu\
9. high affinity IL-2 receptor lOA
EM
x7B;\D#`i/
10. artificial active immunization S9DXd]6q_
RaLV@>jPm
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 3L2NenJB
C D6N8n]
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óá£
zWPX
`JV(ae0
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 1z|bQ,5
I[rR-4.F]
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ o]V.6Ge-
{Zw;<1{E
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ tvno3
"
*Mg@j;+5s
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) ;4dFL\KU
NHUJ:j@
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ f4,|D |
bGB$a0
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? @}PXBU
byP< !p*
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ,_$J-F?
7V@r^/`8N
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 2\&3x}@
2aR9vmR
¡¡ A|K=>7n]U
[QMN0#(h
AMB{Fssz
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Q)XH5C2X
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ 4dN <B U
>jiez,
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ A#K<5%U{Mv
1D)0\#><
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© f
tl$P[T
'y>Y */
1. immunoglobulin gene rearrangement ?Hdu=+ZV
cGm?F,/`
2. the common chain of cytokine receptor (or a cytokine receptor _pb*kJ
WZHw(BN{+
subunit shared by some cytokine receptors) wjH1Ombt
RiAMW|M"C
3. flow cytometry(FCM) NCT:!&
yFeFI@Hp 3
4. carrier effect /zXOtaG
m rsmul{
5. positive selection of T lymphocytes in thymus qs\Cwn!
[aA@V0l
6. mouse TH1(Th1) and TH2(Th2) subsets vC@^B)5gb
&V~l(1
7. perforin (pore-forming protein ,PFP) ;>5`Y8s6
,>b>
I#{
8. ADCC(antibody-dependent cell-mediated cytotoxicity) w$9LcN
kD;pj3o&"2
9. SH-2(src-homology region 2) P33xt~
[yk-<}#B
10. Ab2¦Â (internal image) B1!xr-kC
MomHSv Q\
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© D@68_sn
KfBT'6t
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? 3Y2~HuM
!*"fWahv
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? a=j'G]=
T{3nIF
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠoS..y($TI
_7;:*'>a4
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ v
'+]T=
_,T
4DS6
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óá£
%Rn*oV
m!%aB{e
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) R'tK
J_VI
3)W zX
ÃâÒßѧרҵ£º + tMf&BZ
/v+)#[]>
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ^HJ?k:u
g5@g_~ g
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? _5-h\RB)
!&rd#ZBn
´«È¾²¡Ñ§×¨Òµ£º MY@&^71i4
rR#Ditn^
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ]h,rgO;
]A3
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ;Y^'$I2fR#
O1z]d3x
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ !=YKfzE
BHUI1y5t
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? {?H5Pw>{%h
h= sNj
/D&&7;jJ
nMyl(kF[
Cd}^&z
gA!@oiq@
pd|KIs%jl
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ -!j6&
*5%vU|9b
ÃâÒßѧÊÔÌâ T-en|.
gc.Lh~
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© c1yRy|
.S/5kLul
1. Fas(CD95)/FasL D:1@1Jr
K
tq 4b%{
2. common chain of cytokine receptor Re,;$_6o
K92j BR
3 . TCR/CD3 complex =nhY;pY3u
q!$s<n
4. negaive selection of thymocytes bhqSqU}6~
.^Sglo
5. artificial active immune X Q#K1Z
4S<M
9A}
6. anti-idiotypic ?QOU9"@+B
b@Ej$t&
7. IgSF V`Cyx^P
DB/~Z
8. Integrin *F\wWg'!B
\^!;r 9z=A
9. chemokine K*/oWYM]
Er;/zxg9p
10. B7/CD28 F9fLJol
2XP
}:e
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© dli(ckr
1'~Xn
4
f
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ p*;!5;OUR
R#T-o,m
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ J @Hg7Faz
s L^+$Mq6
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ lLD#|T3
mY"7/dw<v
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ 6TP
/0o)
1d5%(:@
%*R, ceuI
bMO^}qR`
D2$9$xeR
j-<-!jTd
AO-5>r
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ roADC?@r
[l}H:%O,
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© c]6b|mHT
c4H6I~2Na
1. B7/CD28 5X{|*?>T
]
K$YtM^
2. Th1 subset JipNI8\r
j~q 7v
`":
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© Ac:`xk<
]A5F}wV4
4. antibody affinity maturation S\GWMB!oF
\s=r[0tj!
5. AP-1 Mu3G/|t(
NI?
O
6. single chain variable fragment£¨ScFv£© ;hT3N UCA
UmR)L!QT8
7. NK cell receptor 'uu*DgEr
j7}mh
8. Zinkernagel-Doherty phenomenon Y@FYo>0O
E !kN h
9. Ig fold u?,>yf.;s
a 0SZw
10. CD40/CD40L hK?GIbRZ
EyK!'9~a
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© PQaTS*0SXJ
SeHrj&5U
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Ag8/%a~(
ka_m
Q<{9
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ f ,e]jw@
RP~nLh3=\
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ u`v&URM
ilL%
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ Kbu>U{'
!oH{=.w
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ sc*R
:"
`l45T~`]$
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ qc(e3x
3EY
Ed39E
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ "L.k
m
7;Ze>"W>
L}
R"
1O
xd{.\!q.
WN]k+0#
0(i3RPIj\
l~$
)>?ZD
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (1x8DVXNN
ZV{C9S&
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© du$lS':`
faOiNR7;h
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© hTa X@=Ra
qt9jZtx
1.Co-stimulators (or co-stimulating molecules) D2VYw<tEA
&
en2t=a
2.NK-kB ]#NfH-T
J4eU6W+ {
3.Immunoglobulin superfamily qG,h
1
=w`Mc\o "
4.antigen-presenting cell (APC) g@ J F
,q%X`F
rc
5.death domain i\lvxbp
!{*yWpZ:
6.CCR and CXCR 9 ] N{8
(}wPu&Is,C
7.Lectin (or mitogen) OybmyGHY
^+-
QY\N
j
8.Clusters of differentiation, CD) i;pg9Vw
iJdJP)!tz6
9.B7 family . AA#
G
L+ew/I>:
10.Cytotoxic T lymphocyte, CTL) KT<i%)t2
@[joM*U
11.IL-15 and IL-15 receptor (IL-15R) _*=4xmB.=
*0oa2fz%
12.MHC restriction AHr^G
'
S7J.(;
82
13.Affinity-chromatography y}FG5'5$13
\_u{ EB'b
14.Cyctosprin A, CsA 2.JrLBhN
O.#Rr/+)
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 2@T0QJ
W|{!0w
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
Uf_mwEE
;s~xS*(C
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 .z$UNB(!M
%1cxZxGT
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ kLs{B
sMAH;'`!Eu
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ _@?I)4n|
T+0z.E!~I
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© P\
[K)N/ 1
W@GU;Nr
ÃâÒßѧרҵ£º QHXpX9
b* n#XTV
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ eJ[+3Wh
}|-8-;
Ïû»¯ÄÚ¿Æ£º Grw[h
^eoW+OxH
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ C<QpUJ`k
ho#<?rh_
ѪҺ²¡Ñ§×¨Òµ£º oN
83`Z
!}`[s2ji
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ 1*#hIuoj'
)abH//Pps.
),o=~,v:
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Z@JTZMN_
KKg\n^
(רҵ»ù´¡: ÃâÒßѧ) <|3F('Q"
ca,JQrm
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 2nFr?Y3g,
Mu" vj*F
1. ADCC(antibody dependent cell-mediated cytotoxicity) 5M>SrZH
4dz Ym+vJm
2. »·æß¾úËØ(cyclosporin) 1?TgI0HS
\WUCm.w6\%
3. KIR(killer cell inhibitory receptor)
kmJ<AnK
g]b%<DJ
4. HLDA(human leucocyte differentiation antigen) /HSg)
@71y:)W<
5. Interleukin 18(IL-18) vMXn#eR
FGo)]U
6. ÕûºÏËØ(integrin) ~vZ1.y4
Pl|*+g
7. Fas/FasL 'F1<m^
A~a7/N6s;
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) *:chN' <
xLbF9ASim
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) MA mjoH
SwH #=hg
10. Th1/Th2 eYg0NEq{
=*WfS^O
11. »ùÒòÒßÃç(DNAÒßÃç) 8L))@SA+uJ
yAJrdY
"
12. chemokines and chemokine receptor y$|O
E%S
H//,qxDc
13. ÃâÒßÄÍÊÜ `LWb L*;Y0
PiX(Ase
14. ¹²´Ì¼¤·Ö×Ó 7YU}-gi
Js,.$t
15. ËÀÍö½á¹¹Óò(death domain) )]JQlm:H
tH4+S?PI
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) V#-8[G6Ra
lHgmljn5u
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? wIQt
f|ZI>
DB+.<
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ5lm>~J!/^
z`y^o*qc]
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î /3 ;t
&]
@(e/Y/
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
+r]2.
?7aeY5
p
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå AhSN'gWpbF
:\G`}_db'
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ ?xCWg.#l4V
c0:`+>p2
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£